The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The Institute of Cancer Research, ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos Scientists have ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

The PARP inhibitor story begins in the mid-1990s when a team of ICR scientists – including our former Chief Executive Professor Alan Ashworth and Sir Mike Stratton, now Director of the Wellcome Trust ...

The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, ...

In the largest and most comprehensive study of its kind, researchers have provided further evidence that a hormone responsible for regulating breast development acts as a risk factor for breast cancer ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

Professor Paul Workman was 37 and already well established as a cancer researcher when his mother, Ena, died aged 68 from a rare bone tumour known as chordoma. About one in a million people are ...